12 Best Strong Buy Penny Stocks to Invest In Now
The article says Jeremy Siegel, on CNBC’s “Closing Bell,” expects markets to rise as upcoming earnings show fewer warnings and volatility eases. It also notes oil holding in the low 70s despite no Iran-US deal. It then lists 12 “strong buy” penny stocks under $5, including Keel Infrastructure (KEEL) and Incannex Healthcare (IXHL), citing Citizens’ $10 target for KEEL and a USPTO patent for IXHL.
How this was made
The 30-second read
Why it matters
The only actionable, company-specific facts provided are (1) KEEL’s Russell 3000 membership effective date and (2) IXHL’s USPTO patent grant and cited expiry baseline. No new earnings, guidance, trial results, or FDA decisions are disclosed.
Market read
Traders may view the patent grant (IXHL) as supportive for biotech sentiment and KEEL’s index inclusion as a potential flow tailwind, but the article lacks fresh financial or clinical catalysts.
What to watch
For KEEL, the article does not quantify backlog, customer contracts, or margins. For IXHL, it does not provide clinical efficacy updates or FDA approval timelines, which are typically what drive valuation.
Background
The piece is a promotional-style list of “12 best strong buy penny stocks,” using a screener and hedge-fund popularity, with commentary from Jeremy Siegel on market volatility and earnings.
Ticker impact
Keel Infrastructure added to the Russell 3000 effective July 29, 2026, and the article cites Citizens’ Outperform note tied to AI data-center compute demand.
Mild positive bias from passive/index-tracking demand; magnitude likely limited without fresh earnings or contract details.
The only concrete, company-specific catalysts described are Russell 3000 membership and an analyst initiation/price target, not new operating metrics.
Incannex Healthcare received a USPTO patent grant for IHL-42X for obstructive sleep apnea, with baseline expiry cited as July 9, 2040.
Moderately positive reaction potential, especially for biotech momentum, though the article lacks trial readouts or FDA timing.
Patent grant is a tangible regulatory/IP milestone, but no efficacy, enrollment, or FDA decision timing is provided.
Market effects
Highlights two themes traders watch: AI data-center power/compute infrastructure and biotech IP milestones.
Primarily US-focused equities via NASDAQ listings and US patent/regulatory context.
Limited; the article’s macro oil/Iran commentary is generic and not tied to specific company fundamentals beyond sentiment.
Counterpoint
Index reconstitution and analyst initiations may already be priced, and a patent grant does not guarantee clinical success or near-term revenue.
Key entities
- equity issuerKeel Infrastructure Corp.
Added to the Russell 3000 effective July 29, 2026, per the article, and positioned as AI data-center compute infrastructure.
- equity issuerIncannex Healthcare Inc.
USPTO granted a patent for IHL-42X compositions/methods for obstructive sleep apnea, with baseline expiry cited as July 9, 2040.
